MVIR.ST Medivir AB

Healthcare Biotechnology Stockholm Exchange
1.20 SEK
Close of Nov 7, 2026
0.3400 2.89
Market cap
SEK 749M
P/E
-
P/B
2.53x
ROE
-19.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MVIR.ST undervalued?

Graham number

The Graham number of Medivir AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Medivir AB fundamental analysis

No fundamental analysis for Medivir AB yet.

Medivir AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone d…

Full company profile